At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 27 enrolled
Drug / intervention
Cathflo Activase +1 moredrug
Likely dose
Cathflo Activase 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis
In Brief
A Phase 4 clinical trial evaluating Cathflo Activase and Talc Slurry Pleurodesis for Pleural Effusion. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPleural Effusion
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartJun 2021
Primary CompletionDec 2023
TodayJul 2026
First PostedMar 19, 2021
Enrollment StartJun 15, 2021
Primary CompletionDec 14, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.3 years ago
Interventions
Cathflo Activasedrug
Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
Talc Slurry Pleurodesisdrug
Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter